Kornimate/medical-research-clean huggingface dataset:
long term results of psychoeducation and cognitive rehabilitation after mild traumatic brain injury

Conditions: Mild Traumatic Brain Injury

Summary: mild traumatic brain injury (mtbi) accounts for 70-90% of brain injuries, with 600 cases of mtbi per 100 000 people in the united states, but only 100-300 mtbi patients per 100 000 people receive hospital-based care. symptoms reported immediately after injury tend to diminish over the following 10 days and are generally resolved by 3 months. however, in 15-25% of cases , problems persist, and may even worsen, at 3 months. physical, emotional, and behavioral factors can be affected. physical disorders include pain and fatigue. sleep disorders are also common. persistent symptoms can affect patient outcomes (affecting all aspects of life) and increase public healthcare costs .in a previous study (nct03811626, efficacy of psychoeducation and cognitive rehabilitation after mild traumatic brain injury for preventing post-concussional syndrome in individuals with high risk of poor prognosis: a randomized clinical trial. the investigators were able to demonstrate that early multidisciplinary management improved the outcome and prognosis of patients by statistically significantly reducing the percentage of patients with post traumatic syndrome distress at six months (6% for the treated group versus 52% for the control group, p \< 0.001). it seems important to verify that if this short-term improvement (6 months after the trauma) persists in the long term, and therefore at a distance from the end of the initially proposed rehabilitation.

80 mtbi patients included in the previous study (nct03811626) will be contacted by phone and an assessment consisting of questionnaires (qolibri, sf-36, posttraumatic stress disorder checklist scale (pcls ) , proqol) will be offered to them.

Eligibility criteria:
inclusion criteria: * all patients from our previous study nct03811626 and included by our center * patient informed and willing to participate exclusion criteria: * patient without social security

Keywords: mtbi prognosis rehabilitation long term results
human mater and idiopathic infertility

Conditions: Infertility

Summary: approximately 15 percent of couples experience infertility, yet no abnormalities can be detected in the man or the woman. in a number of couples, their embryos unexpectedly slow down growth or stop growth completely. some of these situations may be genetically determined. for instance, a portion of cases may be caused by poor egg quality related to genetic or functional deficiencies in heretofore unidentified human maternal effect genes. a model has been developed of such unexplained fertility by creating a mouse line lacking a critical maternal effect gene. (maternal effect genes produce mrna or proteins that accumulate in the egg and are required for normal early embryonic development.) this pilot project will test the hypothesis that a similar defect may be a cause of human infertility. thirty cubic centimeters of blood will be collected from 40 women who have a clinical history consistent with a defective maternal effect gene. dna from these blood cells will be examined and stored. some of the blood cells will be treated so that they can be frozen and grown in the laboratory to produce more dna in the future. if certain mutations are not found, that means that the prevalence of such mutations is less than 10 percent, and investigators may initiate another study with 100 women. if a common mutation is found in at least four patients, the investigators will seek to collect dna from 150 normal fertile control women for comparison. this project is purely investigational; therefore, findings will not be shared with participants. ...

the pilot investigation will examine the hypothesis that human infertility may be caused by mutations in the human mater gene. we will determine the prevalence of these mutations in a select group of women who have a clinical infertility history consistent with a possible defect in a maternal effect gene. after obtaining informed consent and dna from 100 women, relevant mutations in the mater gene will be searched for by single strand conformation polymorphism analysis.

Eligibility criteria:
* inclusion criteria: women to be included in this study will have a clinical infertility history that would be consistent with a possible defect in a maternal effect gene. this includes women who meet the following criteria: 1. a clinical diagnosis of infertility, 2. never been pregnant, and 3. undergone treatment by in vitro fertilization and had at least 8 fertilized eggs as part of at least one in vitro fertilization cycle that failed to lead to a clinical pregnancy. women who have subsequently achieved a pregnancy by egg donation will be included. women of any age are eligible as long as they have otherwise met the inclusion criteria.

Keywords: maternal effect gene embryonic development infertility
hybrid approach to mirror therapy and transcranial direct current stimulation for stroke recovery

Conditions: Cerebrovascular Accident

Summary: we hypothesize that (1) the hybrid therapy will induce greater improvements on some health-related outcomes compared to other therapies; (2) such benefits will retain at 6-month follow-up; (3) better motor control and brain reorganization will be found in the hybrid therapy than the other therapies; (4) correlations will be found between brain activity and movement kinematics/health-related outcomes.

chronic stroke participants will be recruited from the chang gung memorial hospital and then were randomly assigned to 1 of the 4 groups: mt+tdcs, mt+sham tdcs, mt, and ci groups. the participants in each group receive equivalent amounts of treatment. analysis of covariance (ancova), controlling for the pretest differences, will be separately performed for each outcome measure to test the effects of different intervention groups.

Eligibility criteria:
inclusion criteria: * first episode of stroke in cortical regions * time since stroke more than 6 months * initial motor part of ue of fma score ranging from 24 to 52, indicating moderate to mild movement impairment * no severe spasticity in any joints of the affected arm (modified ashworth scale ≤ 2) * no serious cognitive impairment (i.e., mini mental state exam score≧ 24) * willing to sign the informed consent form. exclusion criteria: * aphasia that might interfere with understanding instructions * visual/attention impairments that might interfere with the seeing of mirror illusion, including hemineglect/hemianopsia * major health problems or poor physical conditions that might limit participation * currently participation in any other research * previous brain neurosurgery * metallic implants within the brain.

Keywords: stroke rehabilitation hybrid therapy mirror therapy transcranial direct current stimulation
xience or vision stent management of angina in the elderly

Conditions: Coronary Artery Disease

Summary: the treatment of complex coronary disease causing limiting symptoms of angina with drug-eluting stent technology will prove superior to bare metal stent technology, with respect to a combined endpoint of mortality, mi, requirement for target vessel revascularisation and severe haemorrhage, in patients aged 80 or above.


Eligibility criteria:
inclusion criteria: * age\>80 * stable angina or acute coronary syndrome * coronary narrowing suitable for stenting that is either ≥15mm long and/or ≤3mm diameter. * any lesion with high risk of restenosis eg chronic total occlusion, bifurcation, severe calcification * any left main stem lesion exclusion criteria: * acute st segment elevation myocardial infarction * cardiogenic shock * platelet count =50 x 109/mm3 * patient life expectancy \< 1 year * known allergies to clopidogrel, aspirin, heparin, stainless steel, iv contrast or stent drug elutant * recent major gi haemorrhage (within 3 months) * any previous cerebral bleeding episode * participation in another investigational drug or device study * patient unable to give consent * clinical decision precluding the use of drug eluting stent

Keywords: percutaneous coronary intervention elderly angina
3d augmented reality mirror visual feedback applied to the treatment of unilateral upper extremity neuropathic pain.

Conditions: Neuralgia

Summary: this study has two objectives. first, to introduce a new virtual reality method that incorporates the mechanisms used in mirror visual feedback through a three-dimensional (3d) augmented virtual reality system. second, to evaluate the efficiency of this new method on a convenience sample of patients presenting with unresolved neuropathic pain (crps, plp, plexopathy, stroke) who were not responding adequately to both pharmaceutical management and traditional mirror therapy.

each patient receives 5 treatment periods over a total period of 1 week, where each treatment period lasts a total of 20 minutes.

Eligibility criteria:
inclusion criteria: * neuropathic pain in the unilateral upper extremity scored by dn4 questionnaire * at least 3 months symptom duration following injury * minimum pain of 40 on a visual analogue scale (vas); * a drug treatment regimen that was stable for at least 2 weeks. * subjects were allowed to participate if they presented with any of the following: (1) a crps diagnosis, in accordance with the international association for the study of pain criteria, phantom limb pain (plp), or spinal cord injury or plexopathy; and (2) an history of being treated before by conventional mirror therapy but, in their case, the mirror therapy failed. exclusion criteria: * bilateral injury, * patients with epilepsy * side effects known to 3d (such as nausea, cephalalgia) * cognitive disorder * poor knowledge of the french language.
awake tracheal intubation in critical care patients

Conditions: Videolaryngoscopy; Intensive Care Unit Syndrome

Summary: tracheal intubation in critical care is a high-risk procedure requiring significant expertise and airway strategy modifications, such as awake intubation with video laryngoscope or flexible endoscope intubation. furthermore, delayed sequence intubation can be used by experts in certain high-risk subgroups. the investigators hypothesise that awake tracheal intubation is associated with a lower incidence of severe adverse events than standard tracheal intubation in critical care patients.

intubation records from 2020 to 2022 were acquired to examine all tracheal intubations of critical care patients at a tertiary hospital. each awake tracheal intubation (awake) case - all of which were performed using a videolaryngoscope with a hyperangulated blade - was propensity matched with two controls (1:2 ratio; standard intubation videolaryngoscopy (vl) and direct laryngoscopy (dl) undergoing general anaesthesia), with similar comorbidities and intubations performed after the induction of anaesthesia (asleep).

Eligibility criteria:
inclusion criteria: * data for all critical care patients requiring tracheal intubation during the study period exclusion criteria: * included incomplete data reports
speech locator in-car performance evaluation

Conditions: Hearing Loss

Summary: listeners will conduct sound quality ratings of recordings talkers in a moving car processed using three different microphone processing strategies: an investigational adaptive directional microphone, an omnidirectional microphone and a fixed directional microphone. participants will listen to the recordings streamed via commercially-available and individually-prescribed hearing aids, and conduct ratings onsite in the lab. the procedure will involve a training session and within-subject repeated measures. stimuli will be randomized.


Eligibility criteria:
inclusion criteria: * adults (18-99 years) with ≥3 months hearing aid experience * binaural, symmetric, sensorineural n2 (mild) to n5 (severe) hearing loss * fluent in english exclusion criteria: * children/teenagers * normal hearing or hearing loss exceeding n5 (severe) by 10 db
pilot study comparing negative pressure dressings to conventional dressings

Conditions: Venous Leg Ulcer

Summary: this study is being conducted to determine how the pico™ negative pressure wound therapy compares to standard care treatment for venous stasis ulcers, as there is no evidence to date.

this is a single-blind, randomized pilot study conducted in patients with bilateral venous stasis leg ulcers. the aim of the study is to compare the rate of healing for venous stasis ulcers when using the pico™ single use negative pressure wound therapy (npwt) system versus standard care. the primary objective is to determine if the pico™ npwt system results in an increased rate of healing when compared to standard of care for the treatment of venous stasis ulcers.

Eligibility criteria:
inclusion criteria: * patient with bilateral venous leg ulcers (one on each lower extremity) (defined as any break in the skin that has either been present for longer than 6 wks or occurred in a person with a history of venous leg ulceration). * the ulcer is required to be venous in appearance (ie: moist, shallow, and of an irregular shape), and judged unlikely to heal within 21 days. * 18 years old or older * have an ankle brachial pressure index of at least 0.8 that was measured within the previous 3 months. exclusion criteria: * • patients on anticoagulants- (ie: warfarin, direct thrombin inhibitors). * patients who have a pressure index measured within the previous 3 months to be greater than 1.20 * patients with venous stasis ulcers greater than 17cm by 17cm. * gross leg edema * severe wound exudate * patients with malignancy in the wound bed or margins of the wound * previously confirmed and untreated osteomyelitis. * patients with necrotic tissue with eschar present. * patients with wounds that involve exposed arteries, veins, nerves, bone fragments or sharp edges. * patients with wounds that requires surgical suction.
development study using vaginal tactile imager

Conditions: Pelvic Organ Prolapse

Summary: the objective is to evaluate and optimize tactile imaging technology in evaluation of tissue elasticity parameters in the female pelvis.

pelvic organ prolapse affects 40-50% of women in us. this study aims to establish a reliable examination procedure, collect data necessary for assessing the performance of vaginal tactile imaging sensors, assess clinical suitability of interface software and correlate elasticity measurements with clinical examination findings for normal versus prolapse conditions of the female pelvis.

Eligibility criteria:
inclusion criteria: 1. no evidence of pelvic organ prolapse and no prior pelvic surgery 2. stage 1 or greater pelvic organ prolapse affecting one or more vaginal compartments 3. no evidence of pelvic organ prolapse with prior pelvic surgery (with or without the use of graft material) exclusion criteria: 1. patients with active skin infection, tissue breakdown or ulceration 2. patients with abnormal vaginal anatomy, including vaginal septum, history of vaginal/pelvic radiation, presence of a vaginal tumor or lesion 3. recent pelvic surgery with less than 3-month interval from surgery
immunogenicity of an intradermal qdenga vaccine among healthy volunteers: a pilot study

Conditions: Dengue

Summary: official title: immunogenicity of an intradermal qdenga vaccine among healthy volunteers: a pilot study

as in the setting of low- to middle-income countries, to demonstrating that lower doses of vaccine via intradermal route can still elicit robust immune responses, thereby lowering the overall cost of vaccination might be particularly meaningful ,with possible extra benefit of experiencing fewer side effects or risk of allergy5, 8. this study goal is to explores the potential of intradermal administration of qdenga, hypothesizing that a lower dose via this route could achieve adequate immunogenicity compared to the standard subcutaneous administration, thus offering a cost-effective alternative particularly in low-resource settings where dengue is most prevalent.

Eligibility criteria:
inclusion criteria: * thai adult aged 18-60 years, who not previously received dengue vaccine. * the subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 3-month follow-up of the study. * individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization * the subject can provide with informed consent and sign informed consent form exclusion criteria: * have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. * be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination. * women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. * have acute infectious diseases, including dengue infection * have severe chronic diseases or condition in progress cannot be controlled. for example, poor controlled dm and uncontrolled ht. * have the history of urticaria 1 year before receiving the investigational vaccine. * have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). * have needle sickness. * have the history of immunosuppressive therapy, cytotoxic therapy or systemic corticosteroids * have received blood products within 4 months before injection of investigational vaccines. * under anti-tuberculosis treatment. * not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

Keywords: safety immunogenicity intradermal qdenga
use of biodesign® otologic graft in tympanoplasty

Conditions: Tympanic Membrane Perforation

Summary: this is a prospective, randomized trial to evaluate tympanoplasty outcomes using biodesign sis graft compared to autologous temporalis fascia, the most commonly used graft for repair of tympanic membrane.

patients 18 years or older will undergo primary tympanoplasty without mastoidectomy. the patients will be randomized into groups receiving biodesign versus autograft temporalis fascia for repair.

Eligibility criteria:
inclusion criteria: * patients undergoing primary tympanoplasty without mastoidectomy. exclusion criteria: * patients with a known biologic sensitivity or a cultural objection to use of porcine materials.
reactogenicity, safety and immunogenicity study of a allantoic split inactivated seasonal influenza vaccine

Conditions: Influenza, Human

Summary: the study is a single centre, phase i, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.


Eligibility criteria:
inclusion criteria: * healthy volunteers of both sexes aged 18-60 years. * persons seronegative against a/h1n1 influenza virus, a/h3n2 and type b (with antibody titers ≤1: 10, according to hemagglutination-inhibition (hi) assay to determine). * literate and willing to provide written informed consent. * a signed informed consent. exclusion criteria: * available in anamnaze volunteer at any allergic reactions. * allergic reactions to chicken proteins, or any preceding vaccination. * acute illness with a fever (37.0 c). * vaccination against influenza in the 2012/2013 season. * seropositive volunteers against a/h1n1 influenza virus, a/h3n2 and type b (with antibody titers greater than 1:10 according hi). * current or recent (within two weeks of enrollment) acute respiratory illness with or without fever. * hypersensitivity after previous administration of any vaccine. * history of chronic alcohol abuse and/or illegal drug use. * any clinically significant abnormal laboratory finding. * a positive pregnancy test for all women of childbearing potential. * administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment. * acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. * history of leukemia or any other blood or solid organ cancer. * seropositive for hiv, hepatitis b surface antigen and/or hepatitis c antibodies. * receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study. * participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study. * subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Keywords: vaccine 1 phase safety
efficacy study of clinical nutrition to treat lung neoplasms and breast carcinoma

Conditions: Lung Neoplasms; Breast Neoplasms

Summary: this study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.we estimate there will be 480 patients accepted.120 patients will receive glse compound,120 patients will recrive maitake mushroom extract compound,120 patients will recrive rinseng compound,and 120 patients will be as blank countrol group.efficacy study of clinical nutrition to treat lung neoplasms and breast carcinoma

glse compound、maitake mushroom extract compound and rinseng compound have different mechanism on enhancing immunity.this clinicaltrial compare them the immune effect in the progress of treating lung neoplasms and breast carcinoma.within the 42 days,we will abide by the plan to evaluate the immunity enhancement by monitoring mmune effector molecules.

Eligibility criteria:
inclusion criteria: * lung cancer and breast cancer patients confirmed by surgery pathology; * ecog physical stamina score of 0\~3 points; * expected lifetime \> 3 months; * need to receive radiation and chemotherapy; * heart, liver and kidney function and blood picture is normal,wbc≥4×109/l, neutrophil count≥ 2 x 109 / l,platelet count≥100×109/l, hemoglobin≥100 g/l; * to follow-up, good adherence exclusion criteria: * allergic to text drug; * pregnancy or lactation women; * suffering from mental illness of not easy to control, * have serious mental or cognitive dysfunction; * can not comply with the experimental scheme or can't cooperate with the follow-up; * the patients who are unfavorable to the subject.

Keywords: clinical nutrition
circulating micrornas in small testicular masses and retroperitoneal post-chemotherapy residual masses.

Conditions: Testicular Cancer

Summary: the purpose of this study is to evaluate the diagnostic performance of circulating micrornas in detecting the presence of germ cell cancer in patients with small testicular mass or retroperitoneal post-chemotherapy residual mass and suitable for testis sparing surgery and retroperitoneal lymph node dissection, respectively.


Eligibility criteria:
cohort a: inclusion criteria: * age \>= 18 years * single testicular lesion, with \< 2 cm diameter and \< 30 % testicular volume involvement; * negative serum tumour markers; * suitable for testis sparing surgery; * informed consent. exclusion criteria: * none cohort b: inclusion criteria: * age \>= 18 years * single/multiple post-chemotherapy retroperitoneal lymph node lesion, with \> 1 cm (non seminomatous) / \> 3 cm (seminomatous) diameter in patients with previous testicular germ cell primary tumour; * negative serum tumour markers; * suitable for retroperitoneal lymph node dissection; * informed consent. exclusion criteria: * none